Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey
Hüls, Anke (Department of Epidemiology and Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA)
Costa, Alberto C. S. (Departments of Pediatrics and of Psychiatry, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA)
Dierssen, Mara (Centro de Investigación Biomédica en Red de Enfermedades Raras)
Baksh, R. Asaad (The London Down Syndrome (LonDownS) Consortium, London, United Kingdom)
Bargagna, Stefania (Fondazione Stella Maris IRCCS, Pisa, Italy)
Baumer, Nicole (Harvard Medical School)
Brandão, Ana Claudia (Hospital Israelita Albert Einstein (Sao Paolo, Brasil))
Carfi, Angelo (Policlinico Universitario Agostino Gemelli IRCCS (Roma, Itàlia))
Carmona Iragui, María (Institut d'Investigació Biomèdica Sant Pau)
Chicoine, Brian (Advocate Medical Group Adult Down Syndrome Center, Park Ridge, IL, USA)
Ghosh, Sujay (Cytogenetics and Genomics Reserach Unit. Department of Zoology, University of Calcutta.Kolkata. West Bengal, India)
Lakhanpaul, Monica (Whttington NHS Trust, London, United Kingdom; Down Syndrome Medical Interest Group, London, United Kingdom)
Manso, Coral (CM: DOWN ESPAÑA, Madrid, Spain)
Mayer, Miguel-Angel (Institut Hospital del Mar d'Investigacions Mèdiques)
Ortega, Maria del Carmen (Hospital Universitario 12 de Octubre (Madrid))
de Asua, Diego Real (Instituto de Investigación Hospital Universitario de la Princesa)
Rebillat, Anne-Sophie (Institut Jérôme Lejeune, Paris, France)
Russell, Lauren Ashley (Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA)
Sgandurra, Giuseppina (Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy)
Valentini, Diletta (Bambino Gesù Children's Hospital)
Sherman, Stephanie L. (Department of Human Genetics, School of Medicine, Emory University, Atlanta, Georgia, USA)
Strydom, Andre (South London and the Maudsley NHS Foundation Trust)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	Health conditions, immune dysfunction, and premature aging associated with trisomy 21 (Down syndrome, DS) may impact the clinical course of COVID-19. The T21RS COVID-19 Initiative launched an international survey for clinicians or caregivers on patients with COVID-19 and DS. Data collected between April and October 2020 (N=1046) were analysed and compared with the UK ISARIC4C survey of hospitalized COVID-19 patients with and without DS. The mean age of COVID-19 patients with DS in the T21RS survey was 29 years (SD = 18). Similar to the general population, the most frequent signs and symptoms of COVID-19 were fever, cough, and shortness of breath. Joint/muscle pain and vomiting or nausea were less frequent (p < 0. 01), whereas altered consciousness/confusion were more frequent (p < 0. 01). Risk factors for hospitalization and mortality were similar to the general population with the addition of congenital heart defects as a risk factor for hospitalization. Mortality rates showed a rapid increase from age 40 and were higher in patients with DS (T21RS DS versus non-DS patients: risk ratio (RR) = 3. 5 (95%-CI=2. 6;4. 4), ISARIC4C DS versus non-DS patients: RR = 2. 9 (95%-CI=2. 1;3. 8)) even after adjusting for known risk factors for COVID-19 mortality. Leading signs/symptoms of COVID-19 and risk factors for severe disease course are similar to the general population. However, individuals with DS present significantly higher rates of medical complications and mortality, especially from age 40. Down Syndrome Affiliates in Action, DSMIG-USA, GiGi's Playhouse, Jerome Lejeune Foundation, LuMind IDSC Foundation, The Matthew Foundation, NDSS, National Task Group on Intellectual Disabilities and Dementia Practices.
Ajuts:	Agència de Gestió d'Ajuts Universitaris i de Recerca 2017-SGR-595 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017-SGR-00519 European Commission 848077 Instituto de Salud Carlos III PT17-0009-0014 Instituto de Salud Carlos III PI18-00335 Instituto de Salud Carlos III PI14-01126 Instituto de Salud Carlos III PI17-01019 Instituto de Salud Carlos III SLT006-17-00119
Nota:	Altres ajuts: This work was also supported by grants from the DCEXS is a 'Unidad de Excelencia María de Maeztu', funded by the AEI (CEX2018-000782-M) and Fundació La Marató de TV3 (20141210 to JF).
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	EClinicalMedicine, february 2021, ISSN 2589-5370

DOI: 10.1016/j.eclinm.2021.100769
PMID: 33644721

13 p, 1.5 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats